Clinical Study of EGFR-TKI Combined with Bevacizumab in Patients with Stage IIIB/IVNon-Small-Cell Lung Cancer Harboring EGFR Mutation and PD-L1 Positive

Clinical Study of EGFR-TKI Combined with Bevacizumab in Patients with Stage IIIB/IV Non-Small-Cell Lung Cancer Harboring EGFR Mutation and PD-L1 Positive

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039415

Enrollment

Unknown

Registered

2020-10-27

Start date

2020-10-13

Completion date

Unknown

Last updated

2021-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small-Cell Lung Cancer

Interventions

experimental group:first- or second-generation EGFR-TKIs combined with Bevacizumab

control group:first- or second-generation EGFR-TKIs

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with NSCLC confirmed by histopathology or cell pathology. 2. According to AJCC eighth edition, patients with stage III B / IV clinical stage and unable to undergo radical surgery. 3. Patients who have not received anti-tumor therapy in the past. 4. The sensitive mutation of EGFR gene (exon 19del, exon L858R) was detected. 5. PD-L1 positive subjects (PD-L1 >= 1%) were detected by immunohistochemistry. 6. Patients with at least one measurable lesion. 7. Subjects with PS score (ECoG) <= 2. 8. Subjects aged 18-80 years. 9. Patients with an estimated survival time of more than 3 months. 10. Subjects with normal bone marrow, kidney, liver, heart and function. 11. The subjects who signed the informed consent, the patients who are willing to accept the treatment plan, can insist on medication and have good compliance.

Exclusion criteria

Exclusion criteria: 1. For the subjects with hypertension and poor drug control, the blood pressure was higher than 140 / 90mmHg after standard antihypertensive treatment. 2. Patients with bleeding risk or thrombotic disease. 3. Patients with uncontrolled other tumors. 4. Patients with active tuberculosis or other serious infectious diseases. 5. Patients with severe adverse reactions and intolerance. 6. The subject of the research without legal capacity or influenced by ethics. 7. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
1-year progression-free survival;	—

Secondary

Measure	Time frame
ORR;PFS;OS;DOR;	—

Countries

China

Contacts

Public ContactHaibo Zhang

Guangdong Hospital of Traditional Chinese Medicine (the Second Affiliated Hospital of Guangzhou University of traditional Chinese Medicine, the Second Clinical School of Guangzhou University of Chines

haibozh@aliyun.com+86 13724123615

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026